Barclays raised the firm’s price target on Boston Scientific to $59 from $56 and keeps an Overweight rating on the shares. The analyst increased estimates following the company’s’ “strong” Q2 beat and increased outlook. While the stock traded off after the results, there are further outperformance and catalysts ahead for Boston Scientific in the second half of 2023, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific management to meet virtually with BTIG
- Boston Scientific price target raised to $61 from $60 at Raymond James
- Boston Scientific price target raised to $61 from $57 at Needham
- Boston Scientific price target raised to $62 from $58 at Canaccord
- Boston Scientific price target raised to $59 from $58 at Oppenheimer